1. Home
  2. NVRI vs DFTX Comparison

NVRI vs DFTX Comparison

Compare NVRI & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

N/A

Current Price

$17.97

Market Cap

1.5B

Sector

Miscellaneous

ML Signal

N/A

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$18.25

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NVRI
DFTX
Founded
1853
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
NVRI
DFTX
Price
$17.97
$18.25
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$40.25
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,240,358,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.72
$14.62
52 Week High
$19.48
$18.70

Technical Indicators

Market Signals
Indicator
NVRI
DFTX
Relative Strength Index (RSI) 44.37 60.08
Support Level $17.86 $16.26
Resistance Level $18.62 N/A
Average True Range (ATR) 0.61 0.97
MACD -0.12 0.08
Stochastic Oscillator 44.71 84.73

Price Performance

Historical Comparison
NVRI
DFTX

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: